Hai-Bin Luo

Dr. Hai-Bin Luo


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ZLZhe Li
Zhe Li
XLXin Li
Xin Li
YHYi-You Huang
Yi-You Huang
YWYaoxing Wu
Yaoxing Wu
RLRunduo Liu
Runduo Liu
HLHai-Bin Luo
Hai-Bin Luo
Significance: Drug repurposing effort for treatment of a new disease, such as COVID-19, usually starts from a virtual screening of existing drugs, followed by experimental validation, but the actual hit rate is generally rather low with traditional computational methods. It has been demonstrated that a new virtual screening approach with accelerated free energy perturbation-based absolute binding free energy (FEP-ABFE) predictions can reach an unprecedentedly high hit rate, leading to successful identification of 15 potent inhibitors of SARS-CoV-2 main protease (M pro ) from 25 computationally selected drugs under a threshold of K i = 4 μM. The outcomes of this study are valuable for not only drug repurposing to treat COVID-19 but also demonstrating the promising potential of the FEP-ABFE prediction-based virtual screening approach.

1 July 2020 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XLXiaoyan Liu
Xiaoyan Liu
ZLZhe Li
Zhe Li
SLShuai Liu
Shuai Liu
JSJing Sun
Jing Sun
ZCZhanghua Chen
Zhanghua Chen
HLHai-Bin Luo
Hai-Bin Luo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.

2 October 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
DZDi Zhang
Di Zhang
ZYZhongju Ye
Zhongju Ye
LWLin Wei
Lin Wei
HLHai-Bin Luo
Hai-Bin Luo
LXLehui Xiao
Lehui Xiao

24 January 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYinuo Wu
Yinuo Wu
ZLZhe Li
Zhe Li
YHYi-You Huang
Yi-You Huang
DWDeyan Wu
Deyan Wu
HLHai-Bin Luo
Hai-Bin Luo

31 August 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
GXGuoyou Xie
Guoyou Xie
XWXu-Nian Wu
Xu-Nian Wu
YLYuyi Ling
Yuyi Ling
YRYalan Rui
Yalan Rui
DWDeyan Wu
Deyan Wu
HLHai-Bin Luo
Hai-Bin Luo
N6-methyladenosine (m6A) modification is critical for mRNA splicing, nuclear export, stability and translation. Fat mass and obesity-associated protein (FTO), the first identified m6A demethylase, is critical for cancer progression. Herein, we developed small-molecule inhibitors of FTO by virtual screening, structural optimization, and bioassay. As a result, two FTO inhibitors namely 18077 and 18097 were identified, which can selectively inhibit demethylase activity of FTO. Specifically, 18097 bound to the active site of FTO and then inhibited cell cycle process and migration of cancer cells. In addition, 18097 reprogrammed the epi-transcriptome of breast cancer cells, particularly for genes related to P53 pathway. 18097 increased the abundance of m6A modification of suppressor of cytokine signaling 1 (SOCS1) mRNA, which recruited IGF2BP1 to increase mRNA stability of SOCS1 and subsequently activated the P53 signaling pathway. Further, 18097 suppressed cellular lipogenesis via downregulation of peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein alpha (C/EBPα), and C/EBPβ. Animal studies confirmed that 18097 can significantly suppress in vivo growth and lung colonization of breast cancer cells. Collectively, we identified that FTO can work as a potential drug target and the small-molecule inhibitor 18097 can serve as a potential agent against breast cancer.

12 April 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
FWFuyan Wang
Fuyan Wang
YLYiliang Li
Yiliang Li
YHYameng Han
Yameng Han
ZYZhongju Ye
Zhongju Ye
LWLin Wei
Lin Wei
LXLehui Xiao
Lehui Xiao